Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Decreases By 61.9%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 23,500 shares, a drop of 61.9% from the February 28th total of 61,700 shares. Currently, 2.6% of the shares of the stock are short sold. Based on an average trading volume of 239,900 shares, the days-to-cover ratio is currently 0.1 days.

Revelation Biosciences Price Performance

REVB traded down $0.06 during midday trading on Friday, reaching $2.70. 9,098 shares of the company’s stock were exchanged, compared to its average volume of 113,667. Revelation Biosciences has a 1-year low of $2.36 and a 1-year high of $60.80. The stock has a market capitalization of $2.44 million, a PE ratio of -0.01 and a beta of 0.17. The business’s 50-day moving average price is $3.84 and its 200 day moving average price is $8.58.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.